

Synthesis of C3, C5, C6, C7, C8, and C9 by Human Fibroblasts

P. GARRED, G. HETLAND, T. E. MOLLNES & G. STOERVOLD

Institute of Immunology and Rheumatology, The National Hospital, Oslo, Blood Bank and Department of Immunology, and Department of Microbiology, Ullevaal Hospital Oslo, Norway

Garred, P., Hetland, G., Mollnes, T.E. & Stoervold, G. Synthesis of C3, C5, C6, C7, C8, and C9 by Human Fibroblasts. *Scand. J. Immunol.* 32, 555-560, 1990

We investigated the ability of human fibroblasts to produce the components of the final common pathway (C3-C9) of complement in vitro by co-culturing an alternative complement activator (agarose beads) with the cells. The test system involved incubation of beads with anti-complement antibodies followed by radioactive-labelled anti-Ig detection antibodies. Subsequently, the beads were examined in a radioimmunoassay. Our results indicate that human fibroblasts produce C3, C5, C6, C7, C8, and C9. A neopeptide selectively expressed on activated C9 was detected, indicating assembly of the terminal complement complex and thus formation of a functional terminal complement pathway by the fibroblasts.

Dr Peter Garred, Institute of Immunology and Rheumatology, Fr. Quamsgt 1, N-0172 Oslo 1, Norway

Complement is an integral part of host defence against invading microorganisms and of the inflammatory process. The system is a complicated network composed of about 25 plasma and membrane-bound proteins that interact upon activation in a precise and highly regulated manner [3]. The major source of the complement proteins is the liver, although numerous investigations have shown that extrahepatic synthesis of complement proteins occurs [2]. These studies indicate the potential of locally produced complement as microbicidal factors and inflammatory mediators. Moreover, enhanced tissue-specific expression of complement genes at inflammatory sites suggests that local production and activation of complement proteins may play a role in the immunopathology of certain autoimmune diseases [16].

Many different extrahepatic cell types have been shown to produce complement components from the classical and alternative pathway including monocytes, endothelial cells, astrocytes, epithelial cells, and fibroblasts [1, 11, 13, 25]. Synthesis of the terminal complement components (C5-C9) has been detected in monocytes [9]. Recently, pneumocytes have also been shown to produce terminal complement proteins [18].

We here report that human fibroblasts are able

to produce components of the final common pathway (C3-C9). Assembly of the terminal complement complex (TCC) on the surface of agarose beads, a potent alternative complement pathway activator, indicates that the proteins were functionally active.

MATERIAL AND METHODS

Cells. The human embryonal fibroblast cell lines were obtained from Flow laboratories, Irvine, UK (MRC-5) and from our own laboratory (He 9). The cells were grown to confluence in 16-mm Costar culture wells (Costar, Cambridge, Mass., USA) in Dulbecco's modified Eagle's medium (DMEM) with glutamine (200 mM), NaHCO₃ (2.0 g/l), and 2% inactivated fetal calf serum, and incubated at 37°C in air with 5% CO₂. Some cells were cultured overnight with 1 µg/ml lyophilized endotoxin (ET) (*Escherichia coli* 026; B6, Difco Lab., Detroit, Mich., USA). All fibroblast cultures were washed ($\times 4$) before the experiments were performed under serum-free conditions in DMEM also containing penicillin (105 IU/l) and streptomycin (0.1 g/l). One milligram (5×10^4) of large Sepharose 4B (S4B) agarose beads (Pharmacia Fine Chemicals, Uppsala, Sweden) was incubated with each cell culture well or medium for 24 or 48 h in the absence or presence of 25 µCi/ml 1-[³H] leucine (sp. act. 110 Ci/mmol; New England Nuclear, Dreieich, FRG) or 1 or 5 µg/ml cycloheximide (Sigma, St Louis, Mo., USA), or with normal human serum for 1 h.

Undiluted supernatants (0.5 ml) were harvested after 24 h and 48 h from cell cultures incubated with or without S4B beads. The beads were then removed by a Pasteur pipette and centrifuged for 5 min at 50 g through a 5-ml layer of Lymphoprep (Nycomed, Oslo, Norway) in conical tubes and washed twice in phosphate-buffered saline containing 2 mg/ml bovine serum albumin (PBSA) to remove protein unspecifically bound to the beads before agarose-bound radioactivity was recorded. Control beads were treated similarly. The binding index ± 1 standard deviation of labelled protein to the basis is defined as: counts per minute (cpm) of beads kept in cell cultures with [3 H]leucine divided by cpm of beads kept in medium with [3 H]leucine.

Preparation of antibodies. Highly specific goat antisera to human C6 and C7 was an appreciated gift from Dr H.J. Müller-Eberhard (Scripps Clinic, La Jolla, Calif., USA). The antibody specificities have previously been described in detail [9]. Rabbit anti-C3d and anti-C5 were obtained from Dakopatts, Copenhagen, Denmark and rabbit anti-C3c and anti-C9 from Behringwerke, Marburg, FRG, and tested as described [4]. Goat anti-C8 was purchased from Atlantic Antibodies Inc., Scarborough, Maine, USA. Monoclonal antibody bH6 against a neoepitope on C3b, iC3b, and C3c and monoclonal antibody aE11 reacting with a neoepitope in C9 were produced in our own laboratory [6, 15]. [125 I]-labelled sheep anti-mouse Ig and donkey anti-rabbit Ig, and peroxidase-labelled sheep anti-mouse Ig and donkey anti-rabbit Ig were purchased from Amersham, Buckinghamshire, UK. Rabbit anti-goat Ig was obtained from Dakopatts and goat anti-rabbit Ig that was used as irrelevant antibody from Vector Lab., Burlingame, Calif., USA.

Binding of antibodies to the agarose beads. Anti-complement antibodies diluted in appropriate dilutions were incubated for 30 min at 37°C with the S4B beads (5×10^4) that had been preincubated for 24 or 48 h with the fibroblast cultures and washed in PBSA. In experiments with goat anti-C6, C7, and C8 rabbit anti-goat Ig were used in a second step. [125 I]-labelled anti-Ig antibodies were added after further washing before testing in the radioimmunoassay. Controls were co-cultured beads incubated with BSA or an irrelevant antibody instead of anti-complement antibodies. Control experiments were also performed with agarose beads incubated in normal human serum for 1 h.

Radioimmunoassay (RIA). Detection of complement bound to agarose beads in RIA was performed in general as previously described [8]. Binding index \pm SD of the antibodies to the beads is defined as: cpm of beads treated in cultures or normal serum and incubated with primary and with or without secondary antibodies and [125 I]-labelled anti-Ig divided by cpm of beads treated in cultures or serum and incubated with BSA or an irrelevant antibody and [125 I]-labelled anti-Ig.

Analyses of fluid phase complement activation products. Complement activation in concentrated culture supernatants ($10 \times$) were assessed in two enzyme immunoassays (EIA) specific to neoepitopes on activation products not expressed in native complement factors. One was specific for C3 activation products, thus evaluating the initial part of the complement cascade [5]. The other assay detected the fluid phase TCC [14].

Examination of C3, C5, C9, and activated C9 (C9neo) in SDS-PAGE and in solid-phase EIA. Concentrated culture supernatants were tested in sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) with subsequent western blot analysis [12, 21]. Detection antibodies were polyclonal anti-C3d, anti-C5, and anti-C9. Furthermore, solid-phase C3, C5, C9, and TCC EIA were constructed. Concentrated supernatants were diluted 1:2 and adsorbed to polystyrene wells (Teknunc, Copenhagen, Denmark) overnight at room temperature antibodies in appropriate concentrations were then added. Subsequently, the reaction was processed with peroxidase-labelled anti-rabbit or anti-mouse antisera.

Statistics. The significance of the RIA results was tested by Student's *t* test. *P* values below 0.05 were considered to be statistically significant. In the solid-phase EIA experiments background ± 2 standard deviation (± 2 SD) was considered significant.

RESULTS

Binding of 3 H-labelled protein and anti-C3 antibodies to S4B beads incubated with fibroblasts

In control experiments there was a specific, and by cycloheximide reducible, binding of tritium-labelled protein to the co-cultured beads (Table I).

Since detection of fibroblast-derived C3, as agarose-bound C3b, is prerequisite for the generation of particle-bound C5 convertase, we tested the binding of anti-C3 antibodies to agarose beads with both the MRC-5 and He 9 cell lines. A significant amount of C3 was found on agarose beads harvested from cultures of both cells after 24 or 48 h of incubation (Table II). Prolonged incubation (48 h) increased the binding index of C3 to the beads. Synthesis of C3 was inhibited by addition of cycloheximide (Table II) or ET (data not shown) to the cell cultures.

Agarose binding of antibodies to the terminal components

To study deposition of the terminal complement components on co-cultured S4B beads, polyclonal antibodies against C5, C6, C7, C8, C9 and a monoclonal antibody against a C9 neoepitope were used (Tables III and IV). S4B beads incubated with the MRC-5 cells were shown to bind all the terminal components except C8, indicating novel synthesis of these components. Cycloheximide inhibited the synthesis of the complement proteins after 24 h (inhibition of C6

TABLE I
and H
beads

S4B b
kept w

MRC-
MRC-

He 9
He 9

The
binding
es + [3 H]
cine (1
*5 μ g

TABLE II.
and He 9

S4B beads
kept with

MRC-5
MRC-5
MRC-5

He 9
He 9
He 9
Serum

The resu
Binding in
incubated
treated in c
2022-3964
Cyclo, cy

was observed after 48 h). Mo
added no significant syntheses
was observed (data not shown)
situation with MRC-5, only
detected on the beads incubated

To investigate whether the
components were assembled
ined the binding of a monoclonal
specifically reactive with a neo-
ized C9 (Table IV). We observed
anti-C9neo antibody binding

TABLE I. Internal labelling of protein. De novo synthesis by MRC-5 and He 9 fibroblast cell lines of protein with affinity for S4B agarose beads

S4B beads kept with	Incubation time (h)	Binding of ^3H -labelled protein to beads co-cultured with fibroblasts	
		- cycloheximide	+ cycloheximide*
MRC-5	24	22.9 \pm 0.8	7.5 \pm 0.5
MRC-5	48	40.8 \pm 0.4	18.1 \pm 3.9
He 9	24	24.0 \pm 1.3	5.3 \pm 0.3
He 9	48	59.5 \pm 4.2	14.5 \pm 2.4

The results are given as the mean \pm SD of three experiments. The binding index is defined as: cpm of beads kept in the cell cultures + [^3H]leucine divided by cpm of beads kept in medium + [^3H]leucine (115 \pm 14).

*5 $\mu\text{g/ml}$.

TABLE II. Detection by RIA of C3 on S4B beads incubated with MRC-5 and He 9 fibroblast cultures or serum

S4B beads kept with	Incubation time (h)	Addition of	Binding index of [^{125}I]anti-Ig to beads incubated with cells or serum and then with	
			Anti-C3c	Anti-C3d
MRC-5	24	—	7.1 \pm 1.1	2.5 \pm 0.6
MRC-5	24	Cyclo	ND	NS
MRC-5	48	—	14.1 \pm 0.4	ND
He 9	24	—	7.8 \pm 1.6	NS
He 9	24	Cyclo	ND	NS
He 9	48	—	13.2 \pm 0.6	ND
Serum	1	—	102.4 \pm 7.1	37.7 \pm 4.2

The results are given as the mean \pm SD of at least two experiments. Binding index: cpm of beads treated in cultures or normal serum and incubated with primary antibody and anti-Ig divided by cpm of beads treated in cultures or serum and incubated with BSA and anti-Ig (range 2022–3964 cpm).

Cyclo, cycloheximide; ND, not determined; NS, not significant.

was observed after 48 h). Moreover, when ET was added no significant synthesis of the components was observed (data not shown). In contrast to the situation with MRC-5, only C6 and C9 were detected on the beads incubated with He 9 cells.

To investigate whether the bound complement components were assembled into TCC, we examined the binding of a monoclonal antibody (aE11) specifically reactive with a neoepitope in polymerized C9 (Table IV). We observed a significant anti-C9neo antibody binding to beads incubated

with the MRC-5 cells. In contrast, no binding of the antibody was observed with beads co-cultured with He 9 cells.

Incubation of S4B beads in serum for 1 h showed binding of C3 and all the terminal components.

Analyses of fluid-phase components

No soluble complement components were found either in fluid-phase EIA, SDS-PAGE, or in solid-phase EIA.

TABLE III. Detection by RIA of C6, C7, and C8 on S4B beads incubated with MRC-5 and He 9 fibroblast cultures or serum

S4B beads kept with	Incubation time (h)	Addition of	Binding index of [¹²⁵ I]anti-Ig to beads incubated with cells or serum and then with rabbit anti-goat Ig and subsequently with		
			Anti-C6	Anti-C7	Anti-C8
MRC-5	24	—	1.8 ± 0.0	NS	NS
MRC-5	24	Cyclo	1.8 ± 0.0	NS	NS
MRC-5	48	—	2.0 ± 0.2	2.3 ± 0.2	NS
MRC-5	48	Cyclo	NS	NS	NS
He 9	24	—	NS	NS	NS
He 9	24	Cyclo	ND	ND	ND
He 9	48	—	2.3 ± 0.2	NS	NS
He 9	48	Cyclo	NS	ND	NS
Serum	1	—	2.9 ± 0.4	3.0 ± 0.6	2.6 ± 0.1

See footnotes to Table II. The range of the cpm values for control beads treated in cultures or serum and incubated with BSA and anti-Ig was 2544–3481.

TABLE IV. Detection by RIA of C5, C9, and TCC on S4B beads incubated with MRC-5 and He 9 fibroblast cultures or serum

S4B beads kept with	Incubation time (h)	Addition of	Binding index of [¹²⁵ I]-anti-Ig to beads incubated with cells or serum and then with:		
			Anti-C5	Anti-C9	aE11
MRC-5	24	—	1.9 ± 0.2	4.9 ± 0.6	2.7 ± 0.1
MRC-5	24	Cyclo	NS	NS	ND
MRC-5	48	—	1.9 ± 0.4	ND	2.0 ± 0.1
MRC-5	48	Cyclo	ND	ND	ND
He 9	24	—	NS	3.7 ± 0.2	NS
He 9	24	Cyclo	NS	NS	ND
He 9	48	—	NS	ND	NS
Serum	1	—	7.0 ± 1.3	26.0 ± 4.4	8.2 ± 0.2

See text to Table II. The range of the cpm values for control beads treated in cultures or serum and incubated with BSA and anti-Ig was 2544–3481.

DISCUSSION

From the present study we conclude that human fibroblasts in vitro synthesize and secrete the complement components C3, C5, C6, C7, and C9 as detected on co-cultured agarose beads by anti-C3, anti-C5, anti-C6, anti-C7, and anti-C9. Furthermore, binding of an antibody specifically recognizing a C9 neopeptide implies that TCC is formed on the beads. This latter finding indicates

that C8 may also be synthesized, since C5b-9 is not formed without generation of C5b-8, although we were not able to detect C8 directly.

De novo synthesis of ³H-labelled protein with affinity for the complement-activating beads was inhibited by cycloheximide. We exclude the possibility that our results are the result of secretion of endocytosed complement, since cycloheximide abrogated detection of complement on the beads. C6 was detected on the beads co-cultured with the

MRC-5 cell line in the presence of serum after 24 h. However, protein synthesis was not revealed de novo synthesis.

Lipopolysaccharide (LPS) has been demonstrated to induce inflammation through the complement system, and to induce protein synthesis in monocytes [2]. We have found that ET, which forms immune complexes, inhibited secretion of complement components in both cell lines. It has been shown to both stimulate and inhibit complement synthesis in fibroblasts.

For unknown reasons, the synthesis of complement components in the culture medium may be possible that secretion of complement components from the fibroblasts is enhanced by contact with other cells or by the presence of observed for perforin, a molecule homologous to C9 which is secreted by activated T cells [22, 23]. Alternatively, complement components and C3 may have been adsorbed to agarose beads and depleted.

Fibroblasts are abundant in most tissues. The extracellular matrix contains elastin, collagen, and proteoglycans. When stimulated, they may secrete complement molecules and present antigens [17, 24]. Moreover, synthesis of complement proteins from both the alternative and classical pathway has been documented [20].

This study demonstrates that fibroblasts also produce a functional complement pathway. Fibroblasts may be a local regulator or the initiator of complement activation in tissues.

ACKNOWLEDGMENT

We thank Ms Ann Teig and Ms. E. H. Colten, excellent technical assistants, for their financial support by the Norwegian Health Organization, the Norwegian Research Council, and the Norwegian Science and the Humanities.

REFERENCES

- 1 Beatty, D.W., Davis, A.E., Colten, H.R. Biosynthesis of complement components.

MRC-5 cell line in the presence of cyclo-heximide after 24 h. However, prolonged incubation (48 h) revealed de novo synthesis of C6 (Table III).

Lipopolysaccharide (LPS) has been demonstrated to induce inflammation, to activate the complement system, and to regulate complement synthesis in monocytes [2]. In the present study we found that ET, which are LPS-protein complexes, inhibited secretion of the complement components in both cell lines. Recently, LPS has been shown to both stimulate and inhibit complement synthesis in fibroblasts [10, 19].

For unknown reasons we failed to detect the components in the culture supernatants. It may be possible that secretion of the terminal components from the fibroblasts may require direct contact with other cells or particles. This has been observed for perforin, a molecule partly homologous to C9 which is secreted from MHC-restricted class I cytotoxic T lymphocytes and NK cells [22, 23]. Alternatively, the terminal components and C3 may have been absorbed to the agarose beads and depleted from the fluid phase.

Fibroblasts are abundant and widely distributed in most tissues. The major secretory products are elastin, collagen, and proteoglycans [7]. When stimulated, they may express MHC class II molecules and present antigens to lymphocytes [17, 24]. Moreover, synthesis of complement proteins from both the alternative and classical pathway has been documented in these cells [10, 20].

This study demonstrates that human fibroblasts also produce a functional terminal complement pathway. Fibroblasts may thus serve as a local regulator or the inflammatory reaction in tissues.

ACKNOWLEDGMENTS

We thank Ms Ann Teig and Astrid Algarra for excellent technical assistance. This work was financially supported by the Norwegian Women's Health Organization, the Nordic Insulin Foundation, and the Norwegian Research Council for Science and the Humanities.

REFERENCES

- 1 Beatty, D.W., Davis, A.E., Cole, F.S., Einstein, L.P. & Colten, H.R. Biosynthesis of complement by human monocytes. *Clin. Immunol. Immunopathol.* 18, 334, 1981.
- 2 Cole, F.S. & Colten, H.R. Complement biosynthesis, Pp. 44-70 in Rother, K. & Till, G.O. (eds). *The Complement System*, 1st edn. Springer-Verlag, Berlin Heidelberg, 1988.
- 3 Frank, M.M. Complement in the pathophysiology of human disease. *N. Engl. J. Med.* 316, 1525, 1987.
- 4 Garred, P., Michaelsen, T.E., Aase, A. & Mollnes, T.E. C3, C4, and the terminal complement complex differ from C1q by binding predominantly to the antigenic part of solid phase immune complexes. *J. Immunol.* 144, 198, 1990.
- 5 Garred, P., Mollnes, T.E. & Lea, T. Quantification in enzyme-linked immunosorbent assay of a C3 neoepitope expressed on activated human complement factor C3. *Scand. J. Immunol.* 27, 329, 1988.
- 6 Garred, P., Mollnes, T.E., Lea, T. & Fischer, E. Characterization of a monoclonal antibody MoAb bH6 reacting with a neoepitope of human C3 expressed on C3b, iC3b, and C3c. *Scand. J. Immunol.* 27, 319, 1988.
- 7 Ham, A.W. & Cormack, D.H. *Histology*, 8th edn J.B. Lippincott, Philadelphia, 1979.
- 8 Hetland, G. & Eskeland, T. Formation of the functional alternative pathway of complement by human monocytes in vitro as demonstrated by phagocytosis of agarose beads. *Scand. J. Immunol.* 23, 301, 1986.
- 9 Hetland, G., Johnson, E., Falk, R.J. & Eskeland, T. Synthesis of complement components C5, C6, C7, C8 and C9 in vitro by human monocytes and assembly of the terminal complement complex. *Scand. J. Immunol.* 24, 421, 1986.
- 10 Katz, Y., Cole, F.S. & Strunk, R.C. Synergism between gamma interferon and lipopolysaccharide for synthesis of factor B, but not C2, in human fibroblasts. *J. Exp. Med.* 167, 1, 1988.
- 11 Katz, Y. & Strunk, R.C. IL-1 and tumor necrosis factor—Similarities and differences in stimulation of expression of alternative pathway of complement and IFN-beta-2/IL-6 genes in human fibroblasts. *J. Immunol.* 142, 3862, 1989.
- 12 Laemmli, U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 227, 680, 1970.
- 13 Levi Strauss, M. & Mallat, M. Primary cultures of murine astrocytes produce C3 and factor B, two components of the alternative pathway of complement activation. *J. Immunol.* 139, 2361, 1987.
- 14 Mollnes, T.E., Lea, T., Froland, S.S. & Harboe, M. Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. *Scand. J. Immunol.* 22, 197, 1985.
- 15 Mollnes, T.E., Lea, T., Harboe, M. & Tschopp, J. Monoclonal antibodies recognizing a neoantigen of poly(C9) detect the human terminal complement complex in tissue and plasma. *Scand. J. Immunol.* 22, 183, 1985.
- 16 Passwell, J., Schreiner, G.F., Nonaka, M., Beuscher, H.U. & Colten, H.R. Local extrahepatic expression of complement genes C3, factor B, C2,

- and C4 is increased in murine lupus nephritis. *J. Clin. Invest.* **82**, 1676, 1988.
- 17 Prober, J.S., Collins, T., Gimbrone, M.A., Cotran, R.S., Gitlin, J.D., Fiers, W., Clayberger, C., Krensky, A.M., Burakoff, S.J. & Reiss, C. Lymphocytes recognize human vascular endothelial and dermal fibroblasts Ia antigens induced by recombinant immune interferon. *Nature* **305**, 726, 1983.
 - 18 Rothman, B.L., Merrow, M., Bamba, M., Kennedy, T. & Kreutzer, D.L. Biosynthesis of the third and fifth complement components by isolated human lung cells. *Am. Rev. Respir. Dis.* **139**, 212, 1989.
 - 19 Rothman, B.L., Merrow, M., Despins, A., Kennedy, T. & Kreutzer, D.L. Effect of lipopolysaccharide on C3 and C5 production by human lung cells. *J. Immunol.* **143**, 196, 1989.
 - 20 Skok, J., Solomon, E., Reid, K.B. & Thompson, R.A. Distinct genes for fibroblast and serum C1q. *Nature* **292**, 549, 1981.
 - 21 Towbin, H., Staehelin, T. & Gordon, J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. *Proc. Natl. Acad. Sci. USA* **76**, 4350, 1979.
 - 22 Tschopp, J. & Conzelmann, A. Proteoglycans in secretory granules of NK cells. *Immunol. Today* **7**, 135, 1986.
 - 23 Tschopp, J., Masson, D. & Stanley, K.K. Structural/functional similarity between proteins involved in complement- and cytotoxic T-lymphocyte-mediated cytotoxicity. *Nature* **322**, 831, 1986.
 - 24 Umetsu, D.T., Katzen, D., Jabara, H.H. & Geha, R.S. Antigen presentation by human dermal fibroblasts: activation of resting T lymphocytes. *J. Immunol.* **136**, 440, 1986.
 - 25 Warren, H.B., Pantazis, P. & Davies, P.F. The third component of complement is transcribed and secreted by cultured human endothelial cells. *Am. J. Pathol.* **129**, 9, 1987.

Received 27 June 1990

Accepted in revised form 23 July 1990

SHORT PAPER

Fcγ Receptor Placenta

E. K. KRISTOFFERSEN

Broegelmann Research Lab
Immunology, The Gade Institute

Kristoffersen
Human Placenta

Fcγ receptors
studied by immunofluorescence
staining of placental tissue of the
and in addition to FcγRIII and
endothelium of trophoblasts
The heterogeneity of different receptors

Einar K. Kristoffersen
Building, 502

In recent years many monoclonal antibodies (MoAb) against the three known Fcγ receptors (FcγR) have been produced, providing new information on the structure and function of FcγR [2, 4, 6]. Three different FcγR have been identified on the basis of their affinity, reactivity with MoAb, and cDNA sequence [1, 2, 15, 18, 19]. FcγRI is a monomer expressed on monocytes, macrophages, neutrophils, B lymphocytes, and eosinophils (CD16) of varying molecular weight. FcγRII is expressed on neutrophils, NK cells, and macrophages. Both FcγRII and FcγRIII are involved in the binding of IgG [2]. There is, however, little information on the distribution of FcγR in normal and inflamed tissue.

FcγR have been demonstrated in various tissues and cell types in human placenta, and attempts have been done to characterize the FcγR in this organ [12, 13]. Placental FcγR have been demonstrated by the binding of IgG-coated erythrocytes [8, 14] to soluble